LIXT

Lixte Biotechnology Holdings Inc

LIXT, USA

Lixte Biotechnology Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colorectal cancer. The company's LB-100 combined with doxorubicin in advanced soft tissue sarcoma is under Phase 1b portion; and LB-100 combined with dostarlimab that is in phase 1b/2 for ovarian clear cell carcinoma. The company has a clinical trial research agreement with the Netherlands Cancer Institute; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; and a development collaboration agreement with the Netherlands Cancer Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California.

https://lixte.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
LIXT
stock
LIXT

Stock Recap: Why LIXT stock attracts global investors - Portfolio Gains Summary & Real-Time Volume Analysis Alerts moha.gov.vn

Read more →
LIXT
stock
LIXT

Lixte Biotechnology shareholders approve board nominees and stock plan amendment By Investing.com Investing.com South Africa

Read more →

Showing 2 of 10

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very High

5.09

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-41.34 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-37.37 %

Low ≤ 2%

High ≥ 10%

Debt to Equity

-

Very High

0.11

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 4.21% of the total shares of Lixte Biotechnology Holdings Inc

1.

HighTower Advisors, LLC

(2.1799%)

since

2025/06/30

2.

Ethos Financial Group LLC

(0.5439%)

since

2025/06/30

3.

Geode Capital Management, LLC

(0.4539%)

since

2025/06/30

4.

Fidelity Extended Market Index

(0.3723%)

since

2025/07/31

5.

Atlas Legacy Advisors, LLC

(0.3019%)

since

2025/06/30

6.

Vanguard Institutional Extnd Mkt Idx Tr

(0.1179%)

since

2025/07/31

7.

Tower Research Capital LLC

(0.073%)

since

2025/06/30

8.

Fidelity Series Total Market Index

(0.062%)

since

2025/07/31

9.

Spartan Total Market Index Pool G

(0.0328%)

since

2025/07/31

10.

UBS Group AG

(0.0244%)

since

2025/06/30

11.

Fidelity Nasdaq Composite Index

(0.017%)

since

2025/07/31

12.

NT Ext Equity Mkt Idx Fd - L

(0.0047%)

since

2025/06/30

13.

Northern Trust Extended Eq Market Idx

(0.0047%)

since

2025/06/30

14.

SBI Securities Co Ltd

(0.0045%)

since

2025/06/30

15.

State St US Extended Mkt Indx NL Cl C

(0.0042%)

since

2025/08/31

16.

Bank of America Corp

(0.0027%)

since

2025/06/30

17.

Spartan Extended Market Index Pool F

(0.0026%)

since

2025/07/31

18.

CLEAR STREET LLC.

(0.0022%)

since

2025/06/30

19.

SSgA U.S. Total Market Index Strategy

(0.0018%)

since

2025/03/31

20.

NT Ext Eq Mkt Indx Fd DC Lending Tier 5

(0.0013%)

since

2025/06/30

21.

NT Ext Eq Mkt Indx Fd DC Lend T3

(0.0011%)

since

2024/12/31

22.

TIAA Trust National Association

(0%)

since

2025/03/31

23.

FNY Investment Advisers, LLC

(0%)

since

2025/06/30

24.

Citadel Advisors Llc

(0%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

-0.3291

EPS Estimate

—

EPS Difference

0

Surprise Percent

null%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(4)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(4.3)
GARP
Not Attractive for GARP(2)
Growth
Weak Growth Prospect(0.5)
Momentum
Moderate Momentum(3.5)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
Low Quality Business(3)
Value
Fair Value(5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.